Client News

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Formycon Included in TecDAX Index of Deutsche Börse

BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco

Newron and Myung In Pharm Announce License Agreement for Evenamide in South Korea

AFYREN Provides Business Update and Announces a €10 Million Sustainable Financing for its Subsidiary AFYREN NEOXY

Formycon and Fresenius Kabi Canada Receive Health Canada’s Approval for FYB202/Otulfi® (ustekinumab), a Biosimilar to Stelara®

ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial

QUANTRO Therapeutics Achieves Breakthrough in Transcriptomic Drug Discovery with First Successful Simultaneous 10-Target Multiplex-Screening

InflaRx Announces Participation in January Events in San Francisco

Abivax Announces a Change to the Composition of its Board of Directors